Eyebright Medical Published its 2024 Environmental, Social and Governance Report
Commitment to Sustainable Development, Social Responsibility, and Corporate Governance HONG KONG, April 23, 2025 /PRNewswire/ -- Eyebright Medical Technology (Beijing) Co., Ltd. ("Eyebright Medical", the "Company", Stock Code: 688050.SH, together...
Blueprint for trade stability
BEIJING, April 17, 2025 /PRNewswire/ -- Beijing Review has recently published a government white paper titled China's Position on Some Issues Concerning China-US Economic and Trade Relations. While outlining China's vision for resolving tariff...
Clinical research results for Kelun-Biotech's TROP2 ADC sacituzumab tirumotecan (sac-TMT) published in Nature Medicine, a top international medical journal
CHENGDU, China, April 12, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") today announced that results from a Phase 3 registrational clinical study evaluating the novel TROP2 antibody drug conjugate (ADC)...
The Phase III Study Data of Stapokibart for Seasonal Allergic Rhinitis Published in Nature Medicine
CHENGDU, China, April 6, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") today announced that the prestigious medical journal Nature Medicine has published the results from the Phase III trial of its...
AIM Vaccine reduces losses by nearly 90% in 2024, with the iterative major product series opening up space for explosive growth in performance
HONG KONG, March 31, 2025 /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published its 2024 Annual Results announcement on March 30, 2025, the company recorded revenues of RMB 1,285 million in 2024, an increase of...
Science! SDU Researchers Identified the Membrane Receptor for Ceramide in Adipocytes
JINAN, China, March 26, 2025 /PRNewswire/ -- Recently, Professor Sun Jinpeng's team at Shandong University and collaborators published a research paper titled "Metabolic signaling of ceramides through the FPR2 receptor inhibits adipocyte...
NEXTBIOMEDICAL, Fast Resorbable Microsphere 'Nexsphere-F' : Clinical Study Results on 155 Patients Published in the JVIR
Safety and Excellent Pain Relief Effect after Musculoskeletal Pain Embolization SEOUL, South Korea, March 17, 2025 /PRNewswire/ -- NEXTBIOMEDICAL CO., LDT, announced that clinical study results of Nexsphere-F™, a resorbable embolic agent for...
AIM Vaccine reported a significant reduction in losses for 2024, with several major products set to launch that are expected to drive substantial revenue growth
HONG KONG, March 17, 2025 /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement on March 17, 2025, the company's performance in 2024 showed a significant reduction in losses. Preliminary...
BloombergNEF: World's No.1 Inverter Bankability Rating in 2024 for Sungrow
HEFEI, China, March 11, 2025 /PRNewswire/ -- BloombergNEF (BNEF) has published the results of its 2024 PV Module and Inverter Bankability Survey, naming Sungrow the only inverter supplier to receive a global No.1 rating. This marks the fifth time...
AIM Vaccine's Iteratively Upgraded Diploid Rabies Vaccine Approved for Clinical Trials, Showing Significantly Higher Efficacy than Marketed Diploid Rabies Vaccines
HONG KONG, March 10, 2025 /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement on March 9, 2025, the company's research and development of a diploid rabies vaccine has recently received the...